GlassScriptPhysician profile
Sarah Yagerman
NPI 1568873628
$7,509.57
in general payments reported to CMS, 2019-2025
31 companies · $2,304 in 2025
The $2,304 reported for 2025 was more than what 90% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $450 · 2020: $401 · 2021: $462 · 2022: $576 · 2023: $1,784 · 2024: $1,533 · 2025: $2,304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,352 · Education: $270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,351.60 |
| Education | $269.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,353.32 | 2022-2025 | Tremfya |
| Dermavant Sciences, INC. | $865.01 | 2023-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $770.21 | 2020-2025 | Dupixent, Libtayo |
| Abbvie INC. | $700.04 | 2022-2025 | Botox |
| Incyte Corporation | $626.96 | 2022-2025 | Opzelura |
| Galderma Laboratories, L.P. | $485.97 | 2019-2025 | Nemluvio, Aklief |
| Novartis Pharmaceuticals Corporation | $286.74 | 2020-2025 | |
| Genzyme Corporation | $284.19 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $255.74 | 2019-2025 | |
| Lilly USA, LLC | $250.55 | 2020-2025 | Taltz, Olumiant, Ebglyss |
| Leo Pharma INC. | $202.72 | 2019-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $189.22 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $181.65 | 2021-2025 | Winlevi, Absorica Ld |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $146.71 | 2019-2025 | Cabtreo |
| Amgen INC. | $123.98 | 2023-2025 | Otezla |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $117.38 | 2023-2025 | Zoryve |
| Ucb, INC. | $103.47 | 2023-2025 | Bimzelx, Cimzia |
| Vyne Pharmaceuticals INC. | $80.79 | 2020-2021 | |
| Pfizer INC. | $73.09 | 2019-2022 | |
| Allergan, INC. | $61.14 | 2022 | |
| Kerecis Limited | $57.42 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Almirall LLC | $43.81 | 2020 | |
| Epi Health, LLC | $43.47 | 2021-2022 | |
| Lnhc, INC | $43.36 | 2025 | Zelsuvmi |
| Biofrontera INC. | $34.04 | 2019 | |
| Dermira, INC. | $27.07 | 2019 | |
| Sanofi-Aventis U.S. LLC | $24.04 | 2020 | |
| Merz North America, INC. | $23.98 | 2021 | |
| Celgene Corporation | $23.77 | 2019 | |
| Journey Medical Corporation | $21.81 | 2022 | |
| Prugen, INC. Pharmaceuticals | $7.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Yagerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.